Rachel’s London Marathon 2024 fundraiser for The Institute of Cancer Research (ICR)
Help Rachel Talbot raise money to support The Institute of Cancer Research (ICR)
Help Rachel Talbot raise money to support The Institute of Cancer Research (ICR)
Acting as a caregiver is no easy task. So, being honest about some of the more challenging aspects of it is critical to maintaining your…
In an update of a Norwegian trial, researchers found that long term, salvage reirradiation for locally recurrent prostate cancer was feasible and associated with good…
Tumor intrinsic subtype impacted the association between pCR and EFS after chemotherapy and ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer.
Adam Januszewski, St Bartholomew’s Hospital in London, provides an overview of a session he chaired at the BTOG 2024 congress focusing on therapeutics, particularly exploring…
PURPOSE Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry…
Gottfried E. Konecny, MD, discusses PRO data for mirvetuximab soravtansine derived from the phase 3 MIRASOL trial.
The goal of screening for breast cancer is to find it early, before it has spread to lymph nodes, to reduce breast cancer mortality and…
The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.
Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.